AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Pharmacokinetic and Safety Study of Subcutaneous and Intravenous Anifrolumab Delivered in Healthy Adult Participants
- First Posted Date
- 2024-10-28
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 24
- Registration Number
- NCT06662123
- Locations
- 🇨🇳
Research Site, Wuhan, China
Prospective Registry Investigating Maternal and Infant Outcomes in Anifrolumab Users
- First Posted Date
- 2024-10-26
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 442
- Registration Number
- NCT06659029
A Study to Investigate the Pharmacokinetics of Ethinyl Estradiol and Levonorgestrel When Given Alone and in Combination With Baxdrostat in Healthy Females of Non-childbearing Potential
- First Posted Date
- 2024-10-24
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 48
- Registration Number
- NCT06657105
- Locations
- 🇺🇸
Research Site, Brooklyn, Maryland, United States
Covid-19 Data Analyses in Brazil
Not yet recruiting
- Conditions
- First Posted Date
- 2024-10-22
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 370000
- Registration Number
- NCT06652451
Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure
Phase 4
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-10-22
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 60
- Registration Number
- NCT06651970
- Locations
- 🇬🇧
Research Site, Sutton Coldfield, United Kingdom
A Phase I PK Study of Balcinrenone/Dapagliflozin in Healthy Chinese Participants
- First Posted Date
- 2024-10-21
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 10
- Registration Number
- NCT06651021
- Locations
- 🇨🇳
Research Site, Chengdu, China
Boosting Regional Integration for COP D Care Through Guided Implementation and Audit of Post Exacerbation Transition Bundle
Not yet recruiting
- Conditions
- First Posted Date
- 2024-10-17
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1368
- Registration Number
- NCT06646419
A Study Evaluating the Effect of Inhaled PT007(AS MDI) Versus Placebo MDI and Ventolin Evohaler on Lung Function in Adult Participants With Asthma
Phase 2
Not yet recruiting
- Conditions
- First Posted Date
- 2024-10-16
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 102
- Registration Number
- NCT06644924
- Locations
- 🇺🇸
Research Site, Milwaukee, Wisconsin, United States
Safety and Tolerability of AZD5148 in Japanese Participants
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-10-15
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 16
- Registration Number
- NCT06639997
- Locations
- 🇯🇵
Research Site, Sumida-ku, Japan
A Phase Ib Study of AZD5462 on Top of Dapagliflozin in Participants With Heart Failure and Moderate Renal Impairment
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-10-14
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 40
- Registration Number
- NCT06639087
- Locations
- 🇸🇪
Research Site, Mölndal, Sweden
© Copyright 2024. All Rights Reserved by MedPath